Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 12, 2016 - Issue 1
Submit an article Journal homepage
282
Views
6
CrossRef citations to date
0
Altmetric
Reviews

The importance of drug transporters in human pluripotent stem cells and in early tissue differentiation

Ágota ApátiInstitute of Enzymology, Research Centre for Natural Sciences, Budapest1117, Hungary
,
Kornélia SzebényiInstitute of Enzymology, Research Centre for Natural Sciences, Budapest1117, Hungary
,
Zsuzsa ErdeiInstitute of Enzymology, Research Centre for Natural Sciences, Budapest1117, Hungary
,
György VáradyInstitute of Enzymology, Research Centre for Natural Sciences, Budapest1117, Hungary
,
Tamás I OrbánInstitute of Enzymology, Research Centre for Natural Sciences, Budapest1117, Hungary
&
Balázs SarkadiInstitute of Enzymology, Research Centre for Natural Sciences, Budapest1117, HungaryCorrespondence[email protected]
Pages 77-92 | Published online: 14 Dec 2015

Bibliography

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Chen QX, Hu HH, Zhou Q, et al. An overview of abc and slc drug transporter gene regulation. Curr Drug Metab. 2013;14:253–264.
  • Sereti KI, Oikonomopoulos A, Unno K, et al. Atp-binding cassette g-subfamily transporter 2 regulates cell cycle progression and asymmetric division in mouse cardiac side population progenitor cells. Circ Res. 2013;112:27–34.
  • Beck WT, Grogan TM, Willman CL, et al. Methods to detect p-glycoprotein-associated multidrug resistance in patients’ tumors: consensus recommendations. Cancer Res. 1996;56:3010–3020.
  • Fatima S, Zhou S, Sorrentino BP. Abcg2 expression marks tissue-specific stem cells in multiple organs in a mouse progeny tracking model. Stem Cells. 2012;30:210–221.
  • Golebiewska A, Brons NH, Bjerkvig R, et al. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell. 2011;8:136–147.
  • Zeng H, Park JW, Guo M, et al. Lack of abcg2 expression and side population properties in human pluripotent stem cells. Stem Cells. 2009;27:2435–2445.
  • Apati A, Orban TI, Varga N, et al. High level functional expression of the abcg2 multidrug transporter in undifferentiated human embryonic stem cells. Biochim Biophys Acta. 2008;1778:2700–2709.

•• First demonstration of ABCG2 protein expression, plasma membrane localization (by FACS and confocal microscopy) and function (by Hst dye exclusion) in human ESCs.

  • Padmanabhan R, Chen KG, Gillet JP, et al. Regulation and expression of the atp-binding cassette transporter abcg2 in human embryonic stem cells. Stem Cells. 2012;30:2175–2187.

•• The widest study according to ABCG2 regulation and expression on hPSCs

  • Ozvegy-Laczka C, Laczko R, Hegedus C, et al. Interaction with the 5d3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human abcg2 multidrug transporter. J Biol Chem. 2008;283:26059–26070.
  • Ozvegy-Laczka C, Varady G, Koblos G, et al. Function-dependent conformational changes of the abcg2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface. J Biol Chem. 2005;280:4219–4227.
  • Gillet JP, Gottesman MM. Advances in the molecular detection of abc transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol. 2011;12:686–692.

•• Comprehensive review of methodologies to analyze mRNA expression levels of ABC transporters.

  • Orina JN, Calcagno AM, Wu CP, et al. Evaluation of current methods used to analyze the expression profiles of atp-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther. 2009;8:2057–2066.
  • Erdei Z, Lorincz R, Szebenyi K, et al. Expression pattern of the human abc transporters in pluripotent embryonic stem cells and in their derivatives. Cytometry B Clin Cytom. 2014;86:299–310.
  • Hirata N, Nakagawa M, Fujibayashi Y, et al. A chemical probe that labels human pluripotent stem cells. Cell Rep. 2014;6:1165–1174.
  • Ulvestad M, Nordell P, Asplund A, et al. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochem Pharmacol. 2013;86:691–702.
  • Rottenberg S, Nygren AO, Pajic M, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A. 2007;104:12117–12122.
  • Zander SA, Kersbergen A, van der Burg E, et al. Sensitivity and acquired resistance of brca1;p53-deficient mouse mammary tumors to the topoisomerase i inhibitor topotecan. Cancer Res. 2010;70:1700–1710.
  • Manning CF, Bundros AM, Trimmer JS. Benefits and pitfalls of secondary antibodies: why choosing the right secondary is of primary importance. PLoS One. 2012;7:e38313.
  • Hamada H, Tsuruo T. Functional role for the 170- to 180-kda glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci U S A. 1986;83:7785–7789.
  • Mechetner EB, Roninson IB. Efficient inhibition of p-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A. 1992;89:5824–5828.
  • Sarkadi B, Homolya L, Szakacs G, et al. Human multidrug resistance abcb and abcg transporters: participation in a chemoimmunity defense system. Physiol Rev. 2006;86:1179–1236.
  • Fardel O, Le Vee M, Jouan E, et al. Nature and uses of fluorescent dyes for drug transporter studies. Expert Opin Drug Metab Toxicol. 2015;11:1233–1251.
  • Ozvegy C, Varadi A, Sarkadi B. Characterization of drug transport, atp hydrolysis, and nucleotide trapping by the human abcg2 multidrug transporter. Modulation of substrate specificity by a point mutation. J Biol Chem. 2002;277:47980–47990.
  • Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the mxr/bcrp/abcp gene alter substrate specificity in mxr/bcrp/abcp-overexpressing cells. Cancer Res. 2001;61:6635–6639.
  • Lebedeva IV, Pande P, Patton WF. Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian abc transporters. PLoS One. 2011;6:e22429.
  • Ahmed-Belkacem A, Pozza A, Macalou S, et al. Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (bcrp/abcg2). Anticancer Drugs. 2006;17:239–243.
  • Ivnitski-Steele I, Larson RS, Lovato DM, et al. High-throughput flow cytometry to detect selective inhibitors of abcb1, abcc1, and abcg2 transporters. Assay Drug Dev Technol. 2008;6:263–276.
  • Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183:1797–1806.
  • Wolf NS, Kone A, Priestley GV, et al. In vivo and in vitro characterization of long-term repopulating primitive hematopoietic cells isolated by sequential hoechst 33342-rhodamine 123 facs selection. Exp Hematol. 1993;21:614–622.
  • Zhou S, Schuetz JD, Bunting KD, et al. The abc transporter bcrp1/abcg2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7:1028–1034.
  • Erdei Z, Sarkadi B, Brozik A, et al. Dynamic abcg2 expression in human embryonic stem cells provides the basis for stress response. Eur Biophys J. 2013;42:169–179.

• Together with reference 44, these two papers describe the role of ABCG2 in the defence of human ESCs against harmful effects.

  • Sarkadi B, Orban TI, Szakacs G, et al. Evaluation of abcg2 expression in human embryonic stem cells: crossing the same river twice? Stem Cells. 2010;28:174–176.
  • Fornas O, Garcia J, Petriz J. Flow cytometry counting of cd34+ cells in whole blood. Nat Med. 2000;6:833–836.
  • Vines A, McBean GJ, Blanco-Fernandez A. A flow-cytometric method for continuous measurement of intracellular ca(2+) concentration. Cytometry A. 2010;77:1091–1097.
  • Weidner LD, Zoghbi SS, Lu S, et al. The inhibitor ko143 is not specific for abcg2. J Pharmacol Exp Ther. 2015;354:384–393.
  • Allen JD, van Loevezijn A, Lakhai JM, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin c. Mol Cancer Ther. 2002;1:417–425.
  • Riss TL, Moravec RA, Niles AL, et al. Cell viability assays. In: Sittampalam GS, Coussens NP, Nelson H, et al., editor. Assay guidance manual. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004.
  • Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215–236.
  • Tang L, Bergevoet SM, Gilissen C, et al. Hematopoietic stem cells exhibit a specific abc transporter gene expression profile clearly distinct from other stem cells. BMC Pharmacol. 2010;10:12.

•• This study provided a great deal of information about the expression of ABC transporters in various types of stem cells and highlighted the importance of tissue specificity.

  • Barbet R, Peiffer I, Hutchins JR, et al. Expression of the 49 human atp binding cassette (abc) genes in pluripotent embryonic stem cells and in early- and late-stage multipotent mesenchymal stem cells: possible role of abc plasma membrane transporters in maintaining human stem cell pluripotency. Cell Cycle. 2012;11:1611–1620.

• This paper demonstrated that mRNA expression profile can serve as a tool for identification of the developmental state of the samples.

  • Bhattacharya B, Miura T, Brandenberger R, et al. Gene expression in human embryonic stem cell lines: unique molecular signature. Blood. 2004;103:2956–2964.
  • Ginis I, Luo Y, Miura T, et al. Differences between human and mouse embryonic stem cells. Dev Biol. 2004;269:360–380.
  • Zeng X, Miura T, Luo Y, et al. Properties of pluripotent human embryonic stem cells bg01 and bg02. Stem Cells. 2004;22:292–312.
  • Das B, Bayat-Mokhtari R, Tsui M, et al. Hif-2alpha suppresses p53 to enhance the stemness and regenerative potential of human embryonic stem cells. Stem Cells. 2012;30:1685–1695.

• Together with reference 31, these two papers describe the role of ABCG2 in the defence of human ESCs against harmful effects.

  • Padmanabhan R, Chen KG, Gottesman MM. Lost in translation: regulation of abcg2 expression in human embryonic stem cells. J Stem Cell Res Ther. 2014;4:pii: 24230.
  • Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev. 2010;62:1–96.
  • Roth M, Obaidat A, Hagenbuch B. Oatps, oats and octs: the organic anion and cation transporters of the slco and slc22a gene superfamilies. Br J Pharmacol. 2012;165:1260–1287.
  • Schlessinger A, Yee SW, Sali A, et al. Slc classification: an update. Clin Pharmacol Ther. 2013;94:19–23.
  • Giacomini KM, Huang SM. Transporters in drug development and clinical pharmacology. Clin Pharmacol Ther. 2013;94:3–9.
  • Hediger MA, Clemencon B, Burrier RE, et al. The abcs of membrane transporters in health and disease (slc series): introduction. Mol Aspects Med. 2013;34:95–107.
  • Nigam SK. What do drug transporters really do? Nat Rev Drug Discov. 2015;14:29–44.
  • Bioparadigms [Internet]. [cited 2015 Nov 13]. Available from: http://slc.bioparadigms.org.
  • Yamada T, Yoshikawa M, Kanda S, et al. In vitro differentiation of embryonic stem cells into hepatocyte-like cells identified by cellular uptake of indocyanine green. Stem Cells. 2002;20:146–154.
  • Tanaka Y, Yoshikawa M, Kobayashi Y, et al. Expressions of hepatobiliary organic anion transporters and bilirubin-conjugating enzyme in differentiating embryonic stem cells. Biochem Biophys Res Commun. 2003;309:324–330.
  • Sweeney DE, Vallon V, Rieg T, et al. Functional maturation of drug transporters in the developing, neonatal, and postnatal kidney. Mol Pharmacol. 2011;80:147–154.
  • Spence JR, Mayhew CN, Rankin SA, et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature. 2011;470:105–109.
  • Ma X, Duan Y, Tschudy-Seney B, et al. Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells. Stem Cells Transl Med. 2013;2:409–419.
  • Martovetsky G, Tee JB, Nigam SK. Hepatocyte nuclear factors 4alpha and 1alpha regulate kidney developmental expression of drug-metabolizing enzymes and drug transporters. Mol Pharmacol. 2013;84:808–823.
  • Geier EG, Chen EC, Webb A, et al. Profiling solute carrier transporters in the human blood-brain barrier. Clin Pharmacol Ther. 2013;94:636–639.
  • Iwao T, Toyota M, Miyagawa Y, et al. Differentiation of human induced pluripotent stem cells into functional enterocyte-like cells using a simple method. Drug Metab Pharmacokinet. 2014;29:44–51.
  • Junttila S, Saarela U, Halt K, et al. Functional genetic targeting of embryonic kidney progenitor cells ex vivo. J Am Soc Nephrol. 2015;26:1126–1137.
  • Nakamichi N, Taguchi T, Hosotani H, et al. Functional expression of carnitine/organic cation transporter octn1 in mouse brain neurons: possible involvement in neuronal differentiation. Neurochem Int. 2012;61:1121–1132.
  • Lin T, Islam O, Heese K. Abc transporters, neural stem cells and neurogenesis–a different perspective. Cell Res. 2006;16:857–871.
  • Strazielle N, Ghersi-Egea JF. Efflux transporters in blood-brain interfaces of the developing brain. Front Neurosci. 2015;9:21.
  • Gene cards [Internet]. [cited 2015 Nov 13]. Available from: http://www.genecards.org.
  • Hagenbuch B, Stieger B. The slco (former slc21) superfamily of transporters. Mol Aspects Med. 2013;34:396–412.
  • Ahmadimoghaddam D, Zemankova L, Nachtigal P, et al. Organic cation transporter 3 (oct3/slc22a3) and multidrug and toxin extrusion 1 (mate1/slc47a1) transporter in the placenta and fetal tissues: expression profile and fetus protective role at different stages of gestation. Biol Reprod. 2013;88:55.
  • Lee DG, Lee JH, Choi BK, et al. H(+)-myo-inositol transporter slc2a13 as a potential marker for cancer stem cells in an oral squamous cell carcinoma. Curr Cancer Drug Targets. 2011;11:966–975.
  • Li Q, Shu Y. Role of solute carriers in response to anticancer drugs. Mol Cell Ther. 2014;2:15.
  • Gupta S, Burckhardt G, Hagos Y. Slc22 transporter family proteins as targets for cytostatic uptake into tumor cells. Biol Chem. 2011;392:117–124.
  • Buxhofer-Ausch V, Secky L, Wlcek K, et al. Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy. J Drug Deliv. 2013;2013:863539.
  • Koepsell H. The slc22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med. 2013;34:413–435.
  • Wessler I, Michel-Schmidt R, Dohle E, et al. Release of acetylcholine from murine embryonic stem cells: effect of nicotinic and muscarinic receptors and blockade of organic cation transporter. Life Sci. 2012;91:973–976.
  • Grundemann D. The ergothioneine transporter controls and indicates ergothioneine activity–a review. Prev Med. 2012;54(Suppl):S71–S74.
  • Ishimoto T, Nakamichi N, Hosotani H, et al. Organic cation transporter-mediated ergothioneine uptake in mouse neural progenitor cells suppresses proliferation and promotes differentiation into neurons. PLoS One. 2014;9:e89434.
  • Mai X, Mai Q, Li T, et al. Dynamic expression patterns of imprinted genes in human embryonic stem cells following prolonged passaging and differentiation. J Assist Reprod Genet. 2011;28:315–323.
  • Park SW, Kim J, Park JL, et al. Variable allelic expression of imprinted genes in human pluripotent stem cells during differentiation into specialized cell types in vitro. Biochem Biophys Res Commun. 2014;446:493–498.
  • Yonezawa A, Inui K. Importance of the multidrug and toxin extrusion mate/slc47a family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br J Pharmacol. 2011;164:1817–1825.
  • Motohashi H, Nakao Y, Masuda S, et al. Precise comparison of protein localization among oct, oat, and mate in human kidney. J Pharm Sci. 2013;102:3302–3308.
  • Berveiller P, Degrelle SA, Segond N, et al. Drug transporter expression during in vitro differentiation of first-trimester and term human villous trophoblasts. Placenta. 2015;36:93–96.
  • Ganapathy V. Drugs of abuse and human placenta. Life Sci. 2011;88:926–930.
  • Bottalico B, Larsson I, Brodszki J, et al. Norepinephrine transporter (net), serotonin transporter (sert), vesicular monoamine transporter (vmat2) and organic cation transporters (oct1, 2 and emt) in human placenta from pre-eclamptic and normotensive pregnancies. Placenta. 2004;25:518–529.
  • Necsulea A, Kaessmann H. Evolutionary dynamics of coding and non-coding transcriptomes. Nat Rev Genet. 2014;15:734–748.
  • Gerstein MB, Kundaje A, Hariharan M, et al. Architecture of the human regulatory network derived from encode data. Nature. 2012;489:91–100.
  • Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. Nature. 2012;489:101–108.
  • Jonas S, Izaurralde E. Towards a molecular understanding of microrna-mediated gene silencing. Nat Rev Genet. 2015;16:421–433.
  • Nigam SK, Bush KT, Martovetsky G, et al. The organic anion transporter (oat) family: a systems biology perspective. Physiol Rev. 2015;95:83–123.
  • Hughes TA. Regulation of gene expression by alternative untranslated regions. Trends Genet. 2006;22:119–122.
  • Zong Y, Zhou S, Fatima S, et al. Expression of mouse abcg2 mrna during hematopoiesis is regulated by alternative use of multiple leader exons and promoters. J Biol Chem. 2006;281:29625–29632.

• Together with reference 90, these two papers describe the existence of alternative 5 noncoding exons of the ABCG2 multidrug transporter.

  • Nakanishi T, Bailey-Dell KJ, Hassel BA, et al. Novel 5 untranslated region variants of bcrp mrna are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage. Cancer Res. 2006;66:5007–5011.

•Together with reference 89, these two papers describe the existance of

  • Ding XW, Wu JH, Jiang CP. Abcg2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010;86:631–637.
  • de Boussac H, Orban TI, Varady G, et al. Stimulus-induced expression of the abcg2 multidrug transporter in hepg2 hepatocarcinoma model cells involves the erk1/2 cascade and alternative promoters. Biochem Biophys Res Commun. 2012;426:172–176.
  • Bolton JA, Wood SA, Kennedy D, et al. Retinoic acid-dependent upregulation of mouse folate receptor-alpha expression in embryonic stem cells, and conservation of alternative splicing patterns. Gene. 1999;230:215–224.
  • Ozretic P, Bisio A, Musani V, et al. Regulation of human ptch1b expression by different 5 untranslated region cis-regulatory elements. RNA Biol. 2015;12:290–304.
  • Sugimoto M, Watanabe T, Sugimoto Y. The molecular effects of a polymorphism in the 5 UTR of solute carrier family 44, member 5 that is associated with birth weight in holsteins. PLoS One. 2012;7:e41267.

•• This paper describes the connection between the function of an SLC drug transporter and its 5 UTR sequence variant.

•• This is an important breakthrough paper first describing the role of 3 UTR sequences not only in mRNA decay and translation regulation, but also in mRNA and hence in protein cellular localization.

  • Lebedeva S, Jens M, Theil K, et al. Transcriptome-wide analysis of regulatory interactions of the rna-binding protein hur. Mol Cell. 2011;43:340–352.
  • To KK, Zhan Z, Litman T, et al. Regulation of abcg2 expression at the 3 untranslated region of its mrna through modulation of transcript stability and protein translation by a putative microrna in the s1 colon cancer cell line. Mol Cell Biol. 2008;28:5147–5161.

• Together with reference 101, the two papers describe how the loss of a 3 UTR sequence could be a selective advantage in tumors via the escape of an ABC transporter from miRNA-based repression.

  • To KK, Robey RW, Knutsen T, et al. Escape from hsa-mir-519c enables drug-resistant cells to maintain high expression of abcg2. Mol Cancer Ther. 2009;8:2959–2968.

• Together with reference 100, the two papers describe how the loss of a 3 UTR sequence could be a selective advantage in tumors via the escape of an ABC transporter from miRNA-based repression.

  • Cheng W, Liu T, Wan X, et al. Microrna-199a targets cd44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012;279:2047–2059.
  • Cui H, Zhang AJ, Chen M, et al. Abc transporter inhibitors in reversing multidrug resistance to chemotherapy. Curr Drug Targets. 2015;16:1356–1371. PMID: 25901528.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.